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AbstrAct
Overexpression of cytokine receptor-like factor 2 (CRLF2) due to chromosomal 
rearrangement has been observed in acute lymphoblastic leukemia (ALL) and reported 
to contribute to oncogenesis and unfavorable outcome in ALL. We studied B-ALL and 
T-ALL patients without CRLF2 rearrangement and observed that CRLF2 is significantly 
increased in a subset of these patients. Our study shows that high CRLF2 expression 
correlates with high-risk ALL markers, as well as poor survival. We found that the 
IKZF1-encoded protein, Ikaros, directly binds to the CRLF2 promoter and regulates 
CRLF2 expression in leukemia cells. CK2 inhibitor, which can increase Ikaros activity, 
significantly increases Ikaros binding in ALL cells and suppresses CRLF2 expression 
in an Ikaros-dependent manner. CRLF2 expression is significantly higher in patients 
with IKZF1 deletion as compared to patients without IKZF1 deletion. Treatment with 
CK2 inhibitor also results in an increase in IKZF1 binding to the CRLF2 promoter and 
suppression of CRLF2 expression in primary ALL cells. We further observed that CK2 
inhibitor induces increased H3K9me3 histone modifications in the CRLF2 promoter 
in ALL cell lines and primary cells. Taken together, our results demonstrate that 
high expression of CRLF2 correlates with high-risk ALL and short survival in patients 
without CRLF2 rearrangement. Our results are the first to demonstrate that the IKZF1-
encoded Ikaros protein directly suppresses CRLF2 expression through enrichment of 
H3K9me3 in its promoter region. Our data also suggest that high CRLF2 expression 
works with the IKZF1 deletion to drive oncogenesis of ALL and has significance in an 
integrated prognostic model for adult high-risk ALL.
IntroductIon
Cytokine receptor-like factor 2 (CRLF2), also known 
as thymic stromal lymphopoietin (TSLP) receptor, is a 
type I cytokine receptor. The CRLF2 subunit generates the 
functional receptor for TSLP by forming a heterodimeric 
complex with interleukin-7 receptor alpha (IL7Rα) [1]. 
Both the cytokine and its receptor have been implicated in 
tumorigenesis [2]. Overexpression of CRLF2 in leukemia 
has been reported [3–6] and was correlated with poor 
outcome in pediatric acute lymphoblastic leukemia (ALL) 
[2, 7, 8]. However, the correlation of CRLF2 expression 
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with the prognosis of adult ALL patients has not been fully 
determined.
The mechanisms of CRLF2 overexpression in 
leukemia are not fully understood [2]. Several studies have 
described the correlation between elevated CRLF2 mRNA 
expression and genomic lesions affecting CRLF2 [8]. 
CRLF2 rearrangements (IGH–CRLF2; PAR1 deletion and 
P2RY8–CRLF2) have been reported to result in elevated 
expression of wild-type CRLF2 [3–5, 7]. Overexpression 
of CRLF2 occurs in 15% adult and pediatric ALL [9, 10]. 
However, the CRLF2 rearrangement subtype is reported 
to account for only about half of ALL with high CRLF2 
expression [11, 12].  These findings suggest that factors 
other than CRLF2 rearrangement can be responsible 
for CRLF2 overexpression. IKZF1 deletion occurs in 
43% of pediatric ALL with CRLF2 overexpression 
[11], although it is present in ~80% of Ph-like ALL 
with CRLF2 rearrangement [13].  IKZF1 deletions and 
CRLF2 overexpression were also identified in 12% and 
11%, respectively, of Japanese Ph-like ALL patients, [7]. 
However, it is unknown whether CRLF2 is a direct target 
of IKZF1 or if IKZF1 deletion is associated with increased 
CRLF2 expression in ALL, particularly in cases without 
CRLF2 rearrangement.
 Recently, we reported the IKZF1 global binding 
profiling in ALL cells and found that IKZF1 regulates the 
expression of its targets through chromatin remodeling 
in ALL [14–17]. Our ChIP-seq data showed IKZF1 
binding peaks in the promoter region of CRLF2.  We 
also found that CK2 inhibitors could increase the tumor 
suppressor activity of IKZF1 and act as a functional 
activator of the IKZF1 protein [14–16].  However, it is 
still unclear whether and how IKZF1 regulates CRLF2 
expression. 
Here we examined CRLF2 expression in adult ALL 
patients without CRLF2 rearrangement, and analyzed the 
correlation of CRLF2 expression with prognosis in adult 
ALL patients. We observed high expression of CRLF2 
in high-risk leukemia and this correlates with the poor 
clinical outcome. We also identified that CRLF2 as a 
direct target of IKZF1. IKZF1 binds to and suppresses 
CRLF2 expression in ALL leukemic cells. The CK2 
inhibitor, TBB, which restores IKZF1 tumor suppressor 
activity, increased the suppression of CRLF2 expression 
and IKZF1 knockdown blocks the TBB-induced changes. 
Deletion of IKZF1 is significantly associated with CRLF2 
overexpression in adult ALL. We also found that IKZF1 
suppresses CRLF2 expression by chromatin remodeling 
through recruitment of H3K9me3 to the promoter. Our 
findings indicate that IKZF1 deletion may be responsible 
for the overexpression of CRLF2 in high-risk ALL 
without CRLF2 rearrangement. High expression of 
CRLF2 may work in conjunction with IKZF1 deletion 
to drive oncogenesis of ALL and both of them have 
significance in an integrated prognostic model for adult 
high-risk ALL. 
results
High crlF2 expression is associated with 
poor prognosis in adult All without crlF2 
rearrangement
CRLF2 is highly expressed in the reported microarray 
cohort study of ALL patients (Supplementary Figure 1). 
Here we examined CRLF2 mRNA expression in 100 
newly diagnosed adult ALL patients without CRLF2 
rearrangement (B-ALL 65 cases and T-ALL 35 cases). We 
found that the CRLF2 mRNA level is significantly higher 
in both B-ALL and T-ALL patients when compared to that 
of normal bone marrow controls (Figure 1A). 
We divided the patients into high  CRLF2 expression 
(Quartile 1-Quartile 2) or low expression (Quartile 
3-Quartile 4) groups and analyzed the relationship between 
CRLF2 expression and clinical characteristics in the 
cohort of B-ALL and T-ALL respectively (Supplementary 
Table S1 and S2). High CRLF2 expression in B-ALL 
patients showed a significant association with higher 
median WBC (45.8 × 109/L vs. 19.4 × 109/L, P = 0.035) 
and a higher percentage of WBC ≥ 30 × 109/L (85.7% vs. 
38.9%, P < 0.0001), which are markers of poor prognosis 
in B-ALL (Supplementary Table 1). In addition, patients 
with high CRLF2 expression were more frequently 
positive for the stem cell marker CD34 (85.7% vs. 55.6%, 
P = 0.010) and the myeloid markers CD13 (60.7% 
vs. 33.3%, P = 0.029) and CD33 (59.3% vs. 30.6%, 
P = 0.023), which are indicative of a poor prognosis in 
B-ALL patients. We also observed that the high CRLF2 
expression group had a higher frequency of splenomegaly 
(58.6% vs. 27.8%, P = 0.012), indicating extramedullary 
infiltration. Importantly, detection of Ikaros isoform6 
(IK6), produced by the most common type of IKZF1 
deletion, was statistically higher in the B-ALL patients 
with high  CRLF2 expression (31.0% vs. 8.3%, P = 0.019)
(Supplementary Table 1). 
The T-ALL patients with high  CRLF2 expression 
exhibited a trend toward higher median WBC (82.0 × 109/L 
vs. 24.8 × 109/L, P = 0.256) than those with low CRLF2 
expression. Patients with high CRLF2 expression had 
lower hemoglobin (114.0 g/L vs. 144.0 g/L, P = 0.039), 
as well as higher percentages of blasts in peripheral blood 
(82.0 vs. 33.0, P = 0.032), higher rates of positivity for 
CD34 (71.4% vs. 21.4%, P = 0.006), and CD33 (61.9% vs. 
21.4%, P = 0.036) and higher frequencies of lymph node 
infiltration (90.5% vs. 57.1%, P = 0.039) as compared 
to patients with low CRLF2 expression (Supplementary 
Table 2). No significant differences in CRLF2 expression 
were observed with respect to age, gender, platelet, bone 
marrow blasts or complex karyotype (Supplementary 
Tables 1 and 2). These data indicate that a high level of 
CRLF2 expression is associated with poor prognostic 
markers in this cohort of the adult ALL patients without 
CRLF2 rearrangements.
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We further analyzed the overall survival (OS) in the 
cohort of B-ALL and T-ALL respectively. We found that 
cases with high CRLF2 expression showed significantly 
shorter OS than cases with low CRLF2 expression in 
both B-ALL (13.0 months vs. 33.0 months, P = 0.017) 
and T-ALL (11 months vs. 32.0 months, P = 0.014) 
(Figure 1B and 1C). These data further indicate that high 
CRLF2expression is associated with poor outcome in ALL 
patients without CRLF2 rearrangements.
IKZF1 binds to the promoter of crlF2 and 
regulates its expression in All
To further address the potential link between high 
CRLF2 expression with high-risk markers and poor 
outcome in adult ALL without CRLF2 rearrangement, 
we analyzed transcription factor motifs in the promoter 
region of CRLF2. As we expected, many core Ikaros 
binding motifs (GGGA) were identified in the promoter 
region of CRLF2 (Figure 2A). Notably, our ChIP-seq 
data showed strong binding peaks for IKZF1 in the 
CRLF2 promoter region [14, 15]. qChIP, assays showed 
significant binding of IKZF1 at the CRLF2 promoter 
region in both B-ALL (Nalm6 and 697) and T-ALL (CEM 
and MOLT-4) cells, but very weak binding in U-937 AML 
cells (Figure 2B).  In addition, we observed that IKZF1 
suppresses the promoter activity of CRLF2 by luciferase 
reporter assay (Figure 2C). These data indicate a direct 
effect of IKZF1 on transcription of CRLF2.  Moreover, 
we found that expression of IKZF1 suppresses CRLF2 
Figure 1: correlation of CRLF2 overexpression and correlation with survival in adult All. (A) Comparison of CRLF2 
mRNA level in B-ALL and T-ALL with normal BM control by qPCR. (b–c) CRLF2 expression with overall survival in adult T-ALL 
(B) and B-ALL (C).
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mRNA levels in both Nalm6 (Figure 3A) and CEM cells 
(Figure 3B). Conversely, efficient IKZF1 knockdown 
increased CRLF2 expression in Nalm6 (Figure 3C) 
and CEM cells (Figure 3D). Furthermore, treatment of 
Nalm6 and CEM cells with CK2 inhibitor (TBB) could 
suppress CRLF2 mRNA and protein levels in a dose-
dependent manner (Figure 4A and 4B). CK2 knockdown 
with shRNA also induced the suppression of CRLF2 
expression in Nalm6 (Figure 4C) and CEM (Figure 4D) 
cells. Importantly, IKZF1 knockdown with shRNA could 
block the TBB-induced decrease of CRLF2 expression in 
Nalm6 (Figure 4E) and CEM (Figure 4F) cells. These data 
indicate that CRLF2 is the direct target of IKZF1 and that 
IKZF1 suppresses CRLF2 expression in ALL.
correlation of IKZF1 deletion with high high  
crlF2 expression in primary All
To provide further supporting that that CRLF2 is a 
direct target of IKZF1 and that IKZF1 suppresses CRLF2 
expression, we analyzed the relationship between IKZF1 
deletion and high  CRLF2 expression in primary ALL. We 
found a higher incidence of IK6, the most common protein 
produced by IKZF1 deletion in B-ALL patients in the 
high CRLF2 expression group (31% vs 8.3%, P = 0.019) 
(Supplementary Table 1). Moreover, we found that CRLF2 
expression was significantly higher in patients with 
IKZF1 deletion than in patients without IKZF1 deletion 
(Figure 5A). These data suggest that IKZF1 deletion 
may contribute to high CRLF2 expression in patients. 
Furthermore, treatment of primary ALL cells with the CK2 
inhibitor, TBB, induced an increase in IKZF1 binding at 
the CRLF2 promoter region in both primary B-ALL and 
T-ALL as compared to untreated controls (Figure 5B). 
Assay by qPCR also showed that TBB treatment inhibited 
expression of CRLF2 mRNA in a dose-dependent manner 
(Figure 5C). These results indicate that IKZF1 binds to 
the promoter of CRLF2 and that treatment with CK2 
inhibitors, which can enhance IKZF1 tumor suppressor 
activity, resulted in suppression of CRLF2 expression in 
primary cells. 
enhanced Ikaros activity due to cK2 inhibition 
increases H3K9me3 at the crlF2 promoter 
Our previous publications have reported that IKZF1 
regulates gene expression through chromatin remodeling 
[5, 18]. To further explore the epigenetic mechanism by 
Figure 2: IKZF1 binds the promoters of CRLF2. (A) CRLF2 promoter region with conserved IKZF1 binding motif (red); 
(b) qChIP data for IKZF1 binding on CRLF2 promoter in leukemic cells; (c) The promoter activity of CRLF2 promoters measured by 
luciferase reporter assay following transfection with IKZF1 or control vector in HEK293 cells.  
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Figure 3: IKZF1 suppresses CRLF2 expression. (A–b) Expression of CRLF2 and IKZF1 in Nalm6 cells (A) and CEM T-ALL 
cells (B) transduced with vector containing IKZF1 as compared to control vector. (c–d) qPCR of CRLF2 and IKZF1expression in Nalm6 
cells (C) and CEM cells (D), following IKZF1shRNA treatment as compared to scramble shRNA cells. Gene expression is determined 
by RT-qPCR using total RNA isolated from the cells transfected with scramble shRNA (siControl) or IKZF1shRNA (siIKZF1) for 2 days.
Figure 4: cK2 inhibitor-tbb suppress the expression of CRLF2 in an IKZF1-dependent manner.  (A–b) Effect of CK2 
inhibitor-TBB) which functions as Ikaros activator, on expression of CRLF2 mRNA level (A) and protein level (B) in Nalm6 and CEM cells 
with TBB treatment for 2 days. (c–d) Effect of CK2 knockdown on the expression of CRLF2 in Nalm6 (C) and CEM (D) cells. (e–F) IKZF1 
knockdown rescues the TBB-induced change of CRLF2 in Nalm6 (E) and CEM (F) cells. Cells was treated with 25 µM TBB for 2 days. 
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which IKZF1 regulates CRLF2, we performed ChIP assay 
and amplified the resulting CRLF2 promoter sequences 
with five pairs of primers as shown in Figure 6A.  The 
results showed that TBB, which enhances IKZF1 function, 
significantly increases binding of IKZF1 at the CRLF2 
promoter as compared with that in untreated Nalm6 
B-ALL cells (WT) (Figure 6B). Moreover, TBB also 
clearly enhances the binding of H3K9me3  (a hallmark 
of heterochromatin) at the CRLF2 promoter region in 
Nalm6 cells (Figure 6C). Similar results were observed 
in the CEM T-ALL cell line (Figure 6D). However, we 
did not find enrichment of other histone modification 
markers in the CRLF2 promoter region (data not shown). 
Further, we found that TBB treatment increases both the 
binding of IKZF1 (Figure 5B) and the presence of the 
H3K9me3 histone modification (Figure 6E) at the CRLF2 
promoter in primary ALL cells. These data indicated that 
enhanced IKZF1 activity suppresses CRLF2 expression 
via increased H3K9me3 in its promoter region.  
dIscussIon
Genetic alterations at the CRLF2 locus are associated 
with overexpression of CRLF2 in ALL [15– 18]. CRLF2 
rearrangement occurs at high frequency in Down Syndrome 
ALL [3, 9, 19] and in patients of Hispanic/Latino ethnicity 
Figure 5: IKZF1 binds to the CRLF2 promoters and IKZF1 deletion results in changes of its expression in primary 
All cells. (A) Comparison of CRLF2 expression in patients with or without IKZF1 deletion, presented as CRLF2/GAPDH. The detection 
method for Ik6 (the most common Ikaros deletion) was done as our previously reported (23).  (b) CK2 inhibitor-TBB increased the IKZF1 
binding to the promoters of CRLF2 in primary B-ALL(left) and T-ALL (right) cells. (c) Effect of CK2 inhibitor-TBB functioning as IKZF1 
activator on expression of CRLF2 in primary B-ALL(left) and T-ALL (right) cells with TBB treatment for 2 days.**P < 0.01.
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[21].  However the rate of CRLF2 overexpression occurs at 
a higher frequency in patients than CRLF2 rearrangement 
[9, 22]. Thus CRLF2 rearrangement is unable fully to 
explain the mechanisms underlying CRLF2 overexpression 
in ALL patients.  Here we provide the first report that 
CRLF2 is a direct target of IKZF1 and that IKZF1 regulates 
CRLF2 expression via induction of the H3K9me3 histone 
modification at its promoter (Model see Figure 7). We also 
show that Ikaros deletion is associated with high CRLF2 
which suggests another mechanism, in addition to genetic 
alteration of the CRLF2 locus, is responsible for CRLF2 
overexpression in ALL. 
Figure 6: cK2 inhibitor-tbb by restoring Ikaros function induces transcriptionally repressive epigenetic changes 
at the CRLF2 promoter. (A) Schematic depiction of the qChIP primers used to analyze epigenetic changes following TBB treatment. 
Positions of primers used for qChIP are indicated relative to the CRLF2 transcription start site (TSS). (b–c) The qChIP analysis of the 
distribution of IKZF1 (B) and H3K9me3 (C) at the CRLF2 promoter in Nalm6 cells cultured with or without 50 µM TBB for 2 days. 
(d) The qChIP data of IKZF1 and H3K9me3 enrichment at the CRLF2 promoter in CEM T-ALL cells cultured with or without TBB. 
(e) The qChIP data of H3K9me3 enrichment at the CRLF2 promoter in primary ALL cells cultured with or without TBB. Graphed data are 
presented as mean +/– SEM of  triplicates of  three independent experiments. 
Figure 7: Proposed model of IKZF1 activator inducing suppression of CRLF2 expression. 
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In this cohort study, we focus on ALL patients 
without CRLF2 rearrangement. We found that high 
expression of CRLF2 is correlated with unfavorable 
prognostic factors in the patients. Strikingly, the overall 
survival was significantly shorter in both T-ALL and 
B-ALL patients with elevated CRLF2. These observations 
suggested that CRLF2 overexpression is also correlated 
with high-risk adult ALL even when the CRLF2 locus has 
not undergone rearrangement. 
It is worth noting that we observed expression of 
Ik6 in 18.5% of B-ALL without CRLF2 rearrangement 
and particularly that 75.0% of these IK6+ patients also 
showed overexpressed CRLF2. These data indicate that 
IKZF1 deletion with CRLF2 overexpression but no 
CRLF2 rearrangement may distinguish a subgroup of 
adult ALL patients with unfavorable prognosis. This 
data also revealed the prognostic correlations for IKZF1 
deletion and high  CRLF2 expression in ALL patients. 
More importantly, we observed that CRLF2 expression is 
significantly higher in patients with Ik6, suggesting a role 
for the IKZF1 deletion in the elevated CRLF2 expression. 
Our previous publications have demonstrated 
that IKZF1 exerts anti-tumor effects by regulating the 
expression of its target genes such as c-Myc, PI3KCD, 
KDM5B, etc. [14–17]. Here we observed that IKZF1 binds 
to the promoter region of CRLF2 and directly suppresses 
the promoter activity of CRLF2. Our data provide 
evidence  that IKZF1 suppresses CRLF2 expression and 
conversely, that IKZF1 knockdown increases CRLF2 
expression in ALL cells. We also showed that treatment 
with the CK2 inhibitor, TBB, which can restore/enhance 
Ikaros function, could increase IKZF1 binding at the 
CRLF2 promoter and suppress CRLF2 expression in both 
ALL cell lines and primary cells in an IKZF1 dependent 
manner. These data indicate that CRLF2 is a direct target 
of IKZF1 and that increasing IKZF1 activity increases the 
suppression of CRLF2 expression in ALL. 
We previously reported that IKZF1 regulates gene 
expression through chromatin remodeling [15, 19]. 
Here, we observed that increasing IKZF1 activity via the 
CK2 inhibitor, TBB, increases H3K9me3, a suppressive 
chromatin marker, at the CRLF2 promoter. This indicates 
that suppression of CRLF2 expression via chromatin 
remodeling is also a mechanism underlying IKZF1 anti-
oncogenesis in ALL, particularly high-risk ALL.
In summary, we report that CRLF2 is highly 
expressed and significantly correlated with poor clinical 
outcome in a cohort of adult ALL patients without 
CRLF2 rearrangements. We found that Ikaros deletion 
(characterized by Ik6 expression) is significantly 
correlated with high CRLF2 expression. We are the first to 
show that CRLF2 is a direct target of IKZF1, that IKZF1 
regulates CRLF2 expression, and that restoration of IKZF1 
activity using the CK2 inhibitor, TBB, can suppress 
CRLF2 expression via chromatin remodeling in ALL. 
Our results strongly implicate CRLF2 overexpression in 
conjunction with IKZF1 deletion in the oncogenesis of 
ALL and suggest that these should be integrated in future 
prognostic models for adult ALL patients. 
MAterIAls And MetHods
Patients and samples
Bone marrow (BM) samples from 100 patients with 
newly diagnosed ALL and without CRLF2 rearrangements 
(65 B-ALL and 35 T-ALL) were collected between June 
2008 and June 2015 at the First Affiliated Hospital of 
Nanjing Medical University. Thirty normal bone marrow 
samples were obtained from the volunteer. Written 
informed consent was provided before enrollment in the 
study by all patients and volunteers in accordance with 
the Declaration of Helsinki. The study was approved by 
the Ethics Committee of The First Affiliated Hospital of 
Nanjing Medical University, Jiangsu Province Hospital, 
Nanjing, China. The diagnosis of ALL were made 
according to the morphologic, immunophenotypic, 
cytogenetic and molecular criteria of WHO Diagnosis and 
Classification of ALL (2008). 
cytogenetic and molecular analyses
Cytogenetic analysis, determination of Ik6 [23], 
CRLF2 rearrangements [3, 10, 21],  BCR-ABL fusion gene/ 
Ph chromosome [8, 23] were performed as previously 
described. qPCR was performed with qSTAR SYBR 
Master Mix (OriGene) on StepOne Plus Real-time PCR 
system (Applied Bioscience). In order to quantitate gene 
expression value in patients’ samples, template standards 
and primers against Homo sapiens gene CRLF2 (OriGene, 
USA) and Homo sapiens housekeeping gene GAPDH 
(OriGene, USA) were obtained from OriGeneTechnologies 
(Rockville, MD, USA). Gene expression values of the 
genes of interest (GOI) were achieved in each patient by 
a formula obtained with a scatter graph of the Ct values 
from the serial dilutions of template standard following 
manufacturer’s instruction and as previously reported 
[16, 24]. The expression level of the GOI was subsequently 
normalized to the housekeeping gene, expressed as gene 
expression value of GOI/GAPDH. Each experiment was 
performed in triplicate.  All patients were placed in high 
or low CRLF2 expression groups (Quartile 1-Quartile 
2 vs. Quartile 3-Quartile 4) and the cut-off values were 
determined by SPSS 17.0 [16].
The qPCR for CRLF2 expression was similarly 
performed as above in Nalm6 and CEM cells. The results 
were normalized to those obtained with 18sRNA and 
presented as fold induction over vector controls. Primers: 
18s RNA, Sense:5′-GTAACCCGTTGAACCCCATT-3′, 
Antisense: 5′- CCATCCAATCGGTAGTAGCG-3′;CRLF2 
Sense: 5′- GCCAGACCCGAAATCCATCT -3′, Anti-
sense: 5′- CCTGGAAGTTCCCTTGGTGTAT -3′. 
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cell culture reagents, plasmid construction, and 
retroviral gene transfer 
The Nalm6 [25] and 697 [11] have been previously 
described. CCRF-CEM (CEM), MOLT-4 and U-937 cells 
were obtained from the American Type Culture Collection 
(ATCC, Manassas, VA). Cell lines were cultured in RPMI 
1640 medium (Cellgro, USA) supplemented with 10% 
fetal bovine serum (Hyclone, USA). HEK 293T cells 
were cultured in DMEM (Cellgro) supplemented with 
10% fetal calf serum and 1% L-glutamine (Cellgro). Cells 
were incubated at 37°C in a humidified atmosphere of 
5% CO2. Primary human B-ALL and T-ALL cells were 
cultured in RPMI 1640 medium (Cellgro) supplemented 
with 10% fetal bovine serum (Hyclone). 4, 5, 6, 
7-Tetrabromobenzotriazole (TBB) was purchased from 
Sigma (St. Louis). Cells were cultured with or without 
TBB and collected for total RNA isolation. Human 
HA-tagged IKZF1 retroviral construct and retroviral 
production was described previously [14, 16, 26, 27].
luciferase assay
The promoter of CRLF2 (–1000 bp to +200 bp) was 
cloned into pGL4.15 vector (Promega, WI, USA). The 
transient luciferase assay was performed in HEK293T 
cells using the Promega luciferase assay reagents and 
measured with luminometer following the manufacture’s 
instruction [14, 16]. The firefly luciferase activities were 
calculated as fold change relative to values obtained from 
pGL4.15 vector only control cells, and expressed as a 
percentage of pcDNA3. 1-IKZF1 transfection-induced 
luciferase activity versus that of pcDNA3.1 vector. 
All transfection and reporter assays were performed 
independently, in triplicate, at least three times.
Quantitative chromatin immunoprecipitation 
(qchIP) 
The qChIP assays were performed by incubation 
of the chromatin with antibodies against IKZF1 [14–16], 
H3K9me3 (Abcam, USA) or normal rabbit IgG (Abcam) 
as a control [14–16, 23]. Enrichment of the ChIP sample 
over input was evaluated by qPCR with three or more 
replicates, using specific primers in the promoter region 
of CRLF2 as shown in Supplementary Table 3 (forward: 
5′-AGGGGA AGGGAGGGGAAGGGAAAG-3′, reverse: 
5′-CCCTTTCCTCCCCTCCCCTCCT-3′). Relative concen- 
tration of the qPCR product was presented as the fold 
change of the level of DNA-IKZF1 and DNA-H3K9me3 
samples in comparison to controls. 
IKZF1 shrnA knockdown
The Nalm6 cells were transiently transfected with 
human IKZF1 shRNA constructs in the GFP vector 
(pGFP-v-RS) (Origene) using the Neon Transfection 
System (Invitrogen, USA). We used ascrambled 29-mer 
shRNA cassette in the pGFP-v-RS vector as a control. 
Knockdown of IKZF1 was confirmed by measurement 
of IKZF1 mRNA level with qPCR [14, 16, 27]. Primers: 
IKZF1-F: 5′-GGCGCGGTGCTCCTCCT-3′, IKZF1-R: 
5′-TCCGACACGCCCTACGACA-3′. 
Western blot
Cell lysate from cells was prepared as previous 
reported [28]; Twenty microgram protein was boiled  in 
SDS sample buffer for 10 minutes; the  resulting samples 
were run on SDS-PAGE  and transferred to the membrane. 
Membranes were blocked with 5% nonfat dry milk at 
room temperature for 1 h and then incubated overnight 
at 4°C with primary antibody (anti-CRLF2, 1:500; Santa 
Cruz). After being washed, the membrane was incubated 
with goat anti-rabbit IgG conjugated to horseradish 
peroxidase (1:3000) at room temperature for 2 h. The 
blots were developed by the enhanced chemiluminescence 
technique (ECL Plus, Amersham, Arlington Heights, IL) 
according to the manufacturer’s instructions.  
statistical analysis
We divided patients into high or low CRLF2 
expression groups (Q1-Q2 vs. Q3-Q4) [16, 24]. Overall 
median differences between the two groups were evaluated 
using a Mann–Whitney U-test. Overall frequency 
differences in the two groups were analyzed using a χ2 
test. Survival analysis was calculated using the Kaplan–
Meier method. All statistical analyses were performed 
using the SPSS version 17.0, and P < 0.05 was considered 
statistically significant.
The experimental data were shown as the mean 
value with bars representing the standard error of the 
mean (SEM). Determinations of statistical significance 
were performed using a Student t-test for comparisons 
of two groups or using analysis of variance (ANOVA) 
for comparing multiple groups. P < 0.05 was considered 
statistically significant.
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